Get started
Author

Marion Thibaudin

Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance
2018 · Alexia Karen Cotte, Virginie Aires, et al. · Nature Communications · 371
PDF
Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
2016 · Emeric Limagne, Romain Euvrard, et al. · Cancer Research · 280
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells
2022 · Emeric Limagne, Lisa Nuttin, et al. · Cancer Cell · 231
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
2019 · Mathieu Grapin, Corentin Richard, et al. · Journal for ImmunoTherapy of Cancer · 230
PDF
Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
2019 · Emeric Limagne, Corentin Richard, et al. · OncoImmunology · 211
PDF
Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages
2019 · Emeric Limagne, Marion Thibaudin, et al. · Cancer Immunology Research · 146
Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation
2017 · Emeric Limagne, Marion Thibaudin, et al. · Cell Reports · 143
PDF
Follicular helper-T cells restore CD8 + -dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
2021 · Julie Niogret, Hélène Berger, et al. · Journal for ImmunoTherapy of Cancer · 119
PDF
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
2023 · Marion Thibaudin, Jean-David Fumet, et al. · Nature Medicine · 117
PDF
Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
2020 · Jean-David Fumet, Emeric Limagne, et al. · Cancers · 80
PDF
IRF8-dependent molecular complexes control the Th9 transcriptional program
2017 · Etienne Humblin, Marion Thibaudin, et al. · Nature Communications · 73
PDF
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer
2022 · Marion Thibaudin, Emeric Limagne, et al. · Cancer Immunology Immunotherapy · 70
PDF
Human ectonucleotidase-expressing CD25 high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions
2015 · Marion Thibaudin, Marie Chaix, et al. · OncoImmunology · 57
PDF
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
2020 · Jean-David Fumet, Emeric Limagne, et al. · BMC Cancer · 50
PDF
Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.
2020 · François Ghiringhelli, Benoist Chibaudel, et al. · Journal of Clinical Oncology · 41
Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T-cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite-Stable Colorectal Cancer
2025 · Jean-David Fumet, Charlène Latour, et al. · Cancer Research · 25
Immunological features of coronavirus disease 2019 in patients with cancer
2020 · Marion Thibaudin, Jean-David Fumet, et al. · European Journal of Cancer · 17
PDF
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma
2020 · Julie Niogret, Emeric Limagne, et al. · Cancers · 16
PDF
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer
2023 · Nicolas Roussot, Jean-David Fumet, et al. · BMC Cancer · 13
PDF
Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
2022 · Romain Mary, Fanny Chalmin, et al. · Cancer Immunology Research · 13
PDF
Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer
2021 · Quentin Klopfenstein, Valentin Derangère, et al. · Journal for ImmunoTherapy of Cancer · 12
433P Durvalumab and tremelimumab in combination with FOLFOX in patients with previously untreated RAS-mutated metastatic colorectal cancer: First results of efficacy at one year for phase II MEDITREME trial
2021 · J-D. Fumet, B. Chibaudel, et al. · Annals of Oncology · 10
Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet
2025 · Laura Kalfeist, Fanny Ledys, et al. · Journal of Clinical Investigation · 9
PDF
Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial
2025 · Marion Thibaudin, Nicolas Roussot, et al. · Signal Transduction and Targeted Therapy · 7
PDF
Effect of radiochemotherapy on peripheral immune response in glioblastoma
2024 · Léa Hampe, Susy Daumoine, et al. · Cancer Immunology Immunotherapy · 6
Works count: 91
Citation count: 2,369
H-index: 17
I10-index: 22
Year
Topic
Type